Ligand Pharmaceuticals SG&A Expense (Quarterly) Analysis

Ligand Pharmaceuticals Inc (LGND)

71.25 +1.32 (+1.89%) USD | NASDAQ | May 01, 13:10

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 1994. Upgrade now.

Date	Value
December 31, 2023	15.99M
September 30, 2023	14.66M
June 30, 2023	11.29M
March 31, 2023	10.86M
December 31, 2022	31.13M
September 30, 2022	14.92M
June 30, 2022	12.09M
March 31, 2022	11.92M
December 31, 2021	7.043M
September 30, 2021	12.72M
June 30, 2021	14.71M
March 31, 2021	12.62M
December 31, 2020	25.66M
September 30, 2020	15.02M
June 30, 2020	10.07M
March 31, 2020	9.264M
December 31, 2019	10.28M
September 30, 2019	9.525M
June 30, 2019	10.99M
March 31, 2019	11.09M
December 31, 2018	11.16M
September 30, 2018	9.633M
June 30, 2018	9.294M
March 31, 2018	7.643M
December 31, 2017	7.749M

Date	Value
September 30, 2017	7.032M
June 30, 2017	6.549M
March 31, 2017	7.322M
December 31, 2016	6.795M
September 30, 2016	6.55M
June 30, 2016	7.237M
March 31, 2016	7.069M
December 31, 2015	7.208M
September 30, 2015	4.971M
June 30, 2015	7.225M
March 31, 2015	5.994M
December 31, 2014	5.517M
September 30, 2014	6.742M
June 30, 2014	5.239M
March 31, 2014	5.072M
December 31, 2013	4.42M
September 30, 2013	4.756M
June 30, 2013	4.306M
March 31, 2013	4.502M
December 31, 2012	4.203M
September 30, 2012	4.306M
June 30, 2012	3.858M
March 31, 2012	3.416M
December 31, 2011	3.322M
September 30, 2011	3.962M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

7.043M

Minimum

Dec 2021

31.13M

Maximum

Dec 2022

13.72M

Average

12.09M

Median

Jun 2022

SG&A Expense (Quarterly) Benchmarks